<\/p>\n
Shoppers and clinicians alike are shifting attention to clinical research that lives inside electronic medical records and to genomics that\u2019s useful at the bedside; this matters because integrating research and DNA with routine care promises faster trials, fairer recruitment, and genuinely personalised treatment across whole populations.<\/strong><\/p>\n Essential Takeaways<\/p>\n Clinical trials traditionally ran alongside care, creating paperwork and duplication that clinicians resent; now, embedding research protocols into EMRs promises a smoother, more patient\u2011centric approach, with a quieter, more integrated workflow and fewer manual forms. According to industry reporting, centralising patient data inside EHRs allows teams to build research cohorts directly from routine records, reducing clinician burden and improving data quality. This change matters because it turns the point of care into a real opportunity for research participation rather than an administrative afterthought. For practical use, hospitals should pilot small embedded RCTs first, monitor workflow impact, and scale only after clinician feedback shows reduced friction.<\/p>\n One of the neatest gains from EMR integration is automated eligibility screening that flags patients in real time, right where clinicians work. That means fewer missed opportunities caused by busy teams relying on memory, and broader, more representative trial populations. Oracle and other EHR vendors have pushed these benefits, showing how built\u2011in tools can sift records and surface matches quickly. If you\u2019re choosing tech, look for systems with flexible criteria engines and clear audit trails so you can demonstrate regulatory compliance and protect patient trust.<\/p>\n Major platforms are adding genomics modules so clinicians can order tests and see discrete results inside the chart rather than in separate portals. That makes matching patients to biomarker\u2011driven trials much faster and brings actionable genetics into everyday decisions in oncology, rare disease and beyond. The caveat is consent and data governance: different countries handle genomic consent differently, and fragmented ownership , especially in the US , complicates roll\u2011out. Practically, trusts and health systems should map consent workflows, standardise result reporting and train clinicians to interpret genomic alerts without overwhelming them.<\/p>\n Countries and national projects have amassed huge genomic resources , think whole genomes from hundreds of thousands of volunteers , but most of that data isn\u2019t yet used to change routine care. Studies show that many biobanks linked to EHRs don\u2019t return medically actionable findings to participants, which highlights a gap between having data and using it. The emerging approach in 2026 is \u201cconnected genomics\u201d: integrating sequence data with electronic records and partnering with digital firms to deliver actionable insights. Health systems that want to start should prioritise pilots that demonstrate clear clinical utility and measurable outcomes, and design consent processes that allow future actionable returns.<\/p>\n Sequencing costs have fallen dramatically since the early 2000s, yet the full price of genomic medicine still includes labour, storage and analytics , which makes scale tricky. However, when you widen the lens to whole\u2011system benefits (reduced hospital admissions, preserved productivity, fewer costly late\u2011stage treatments), genomics can look like a sound investment. Policymakers in some regions are already linking health, social and economic datasets to prove that case. For leaders, the ask is practical: run health\u2011economics pilots, partner with local authorities to capture broader societal value, and be transparent about costs and expected returns.<\/p>\n Healthcare leaders should be candid: do we have the data plumbing, governance and consent models to embed research and genomics safely into care? The critical first steps are mapping current workflows, piloting EMR\u2011embedded trials with modest scope, and investing in clinician education so genomic results are acted upon appropriately. Also, start conversations with regulators and partners now about consent harmonisation , it\u2019s much easier to design inclusive programmes up front than to retrofit them later. The payoff is a system where every patient encounter can both improve care and contribute learning.<\/p>\n It’s a small change in process that can make every trial faster, every result more useful, and each treatment a little more personal.<\/p>\n\n
Why embedding trials in the EMR feels like a watershed moment<\/h2>\n
Faster, fairer recruitment when screening happens at the point of care<\/h2>\n
How precision medicine modules are changing clinical decisions<\/h2>\n
Connected genomics: moving from data collection to clinical utility<\/h2>\n
The economics and policy puzzle: why genomics looks expensive but can pay off<\/h2>\n
What leaders should ask now , and what to do next<\/h2>\n
Source Reference Map<\/h3>\n